ERBB2 and neoplasm: Trastuzumab (Herceptin), a humanized monoclonal antibody targets the extracellular domain of human epidermal growth factor receptor 2 (HER2) inhibits tumor cells’ survival and proliferation, and is widely used as an approved medication for early HER2 positive and advanced metastatic cancers.